Neoepobin Patched May 2026

As one patient advocate in the CORONET-2 trial put it: "I don't care about the chemistry. I just know that before the patch, I couldn't button my shirt. Now, I can. For me, Neoepobin is hope. The fact that it's patched is just the detail that made it real." Disclaimer: This article discusses investigational compounds that have not been approved by the FDA or EMA. "Neoepobin Patched" is a trademarked developmental name of NeuroGene Dynamics, Inc. All clinical data mentioned is derived from public preprints and patent filings (WO/2025/124567).

Neoepobin was designed to target the , a tyrosine kinase receptor found primarily on parvalbumin-positive interneurons and astrocytes. However, due to the molecule's high affinity for hydrophobic surfaces, researchers discovered that without a chaperone or a "patch," Neoepobin would bind non-specifically to hepatocytes in the liver and cardiac muscle cells. neoepobin patched

Neoepobin (developmental code: NRG-12β) is a synthetic neuregulin-1 analog. Historically, neuregulins are growth factors crucial for neural development, synaptic plasticity, and myelination. However, native neuregulin-1 has a fatal flaw: it is large, unstable in the bloodstream, and notoriously poor at crossing the blood-brain barrier (BBB). As one patient advocate in the CORONET-2 trial

For patients with PSP, multiple sclerosis, or rare leukodystrophies, the arrival of represents the first credible promise of not just slowing decline, but rebuilding what was lost. For me, Neoepobin is hope